MYC, together with Cohesin and Mediator complexes, predetermines the sensitivity of gastrointestinal cancer to antifolate drugs Overall design: GeCKO library screen with NUGC3 using RTX treatment.

NIAID Data Ecosystem30

Exome array analysis of adverse reactions to fluoropyrimidine-based therapy for gastrointestinal cancer

药物不良反应遗传学

胃肠道癌症治疗

Fluoropyrimidines, including 5-fluororacil (5FU) and its pro-drug Capecitabine, are the common treatment for colorectal, breast, neck and head cancers – either as monotherapy or in combination therapy

NIAID Data Ecosystem20

Weight Loss During Neoadjuvant Therapy is Associated with Poor Response among the Patients with Gastrointestinal Cancer: A Propensity Score Matching Analysis

胃肠道癌症治疗

术前新辅助治疗反应

This work was performed with gastrointestinal cancer patients who underwent neoadjuvant therapy from January 2015 to July 2020 at Guangxi Medical University Cancer Hospital. These data are provided f

NIAID Data Ecosystem30

Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer

胃肠道癌症治疗

免疫联合化疗

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Colony-stimulatin

NIAID Data Ecosystem20

Checklist S1 - Comparison of the Efficacy and Safety of S-1-Based and Capecitabine-Based Regimens in Gastrointestinal Cancer: A Meta-Analysis

资源简介：

相关数据集